RIGLHealthcare · BiotechnologyThe 5 Wall Street analysts covering Rigel Pharmaceuticals, Inc. hold a median 12-month price target of $55 — +7.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Rigel Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RIGL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $85 |
| 17 Aug 2026 | Piper Sandler | Maintains | Neutral | $40 → $49 |
| 17 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 14 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $57 → $85 |
| 14 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $57 |
| 27 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $57 |
| 22 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 5 Nov 2025 | Cantor Fitzgerald | Maintains | Neutral | — |
| 5 Nov 2025 | Jefferies | Upgrade | Buy | — |
| 8 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2025 | Cantor Fitzgerald | Maintains | Neutral | — |
| 7 May 2025 | Cantor Fitzgerald | Maintains | Neutral | — |
| 6 Mar 2025 | Citigroup | Maintains | Buy | — |
| 5 Mar 2025 | B. Riley Securities | Maintains | Neutral | — |
| 5 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RIGL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Rigel Pharmaceuticals, Inc. returned +62.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 34% of US stocks
Cheaper than 39% of US stocks
Cheaper than 37% of US stocks
Higher than 11% of US stocks
Higher than 6% of US stocks
Higher than 96% of US stocks
Higher than 87% of US stocks
Higher than 99% of US stocks
Higher than 97% of US stocks
Higher than 97% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rigel Pharmaceuticals, Inc. has a market value of $958.5M and an enterprise value of $903.1M.
Revenue in the twelve months to 30 June 2026: $276.8M. The latest quarter shrank 22.6% year on year.
Net income over the same four quarters: $321.9M, a 116.3% net margin.
Diluted earnings per share, trailing twelve months: $16.32.
Free cash flow in the twelve months to 30 June 2026: $9.0M.
Trailing P/E: 3.0×; forward P/E: 10.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rigel Pharmaceuticals, Inc. employs 172 people — $1.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rigel Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rigel Pharmaceuticals announced it will report its third-quarter 2026 financial results after market close on Thursday, November 5, 2026.
Why it matters — RIGL watchers can note the scheduled timing for the company’s third-quarter results.
The article describes Rigel as developing a multi-product oncology platform, with VEPPANU’s U.S. launch targeting ESR1-mutated breast cancer. It notes that early launch metrics are excluded from current guidance and valuation multiples, alongside reported double-digit base-business sales growth and high gross margins.
Why it matters — RIGL watchers may find the launch’s potential role in growth beyond its ITP legacy relevant, particularly because early metrics are not reflected in current guidance or valuation multiples.
Rigel said pooled ARROW and TAPISTRY data for GAVRETO in RET fusion-positive solid tumors, showing a 53% overall response rate, will be presented at ESMO Congress 2026. The company also noted analyses of first-line outcomes and quality of life in RET fusion-positive NSCLC, and efficacy and safety in RET fusion-positive thyroid cancer.
Why it matters — The data presentations provide RIGL watchers with clinical findings on GAVRETO across RET fusion-positive cancers.
Rigel Pharmaceuticals announced it has granted equity awards under its Inducement Plan, approved by the Compensation Committee of its Board of Directors, as an inducement material to employees entering employment with the company, in accordance with NASDAQ Listing Rule 5635(c)(4).
Why it matters — Rigel watchers would care because the grants reflect new executive or key employee hiring activity tied to the company's inducement equity program.
Rigel Pharmaceuticals announced that its chief financial officer, Dean Schorno, will participate in one-on-one meetings at Citi's 2026 Biopharma Back to School Conference in New York on September 9. The company also stated he will attend additional investor conferences in September.
Why it matters — Rigel watchers may be interested because the CFO's participation in investor conferences offers opportunities to communicate the company's strategy and outlook to the investment community.
The 5 Wall Street analysts covering Rigel Pharmaceuticals, Inc. have a median 12-month price target of $55, with estimates ranging from $43 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Rigel Pharmaceuticals, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rigel Pharmaceuticals, Inc. 89 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Rigel Pharmaceuticals, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +7.2% from the last close, and Ticker Nerd's factor model ranks Rigel Pharmaceuticals, Inc. 89 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rigel Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RIGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $85 over the next 12 months.
Rigel Pharmaceuticals, Inc. returned +62.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer.
The most recent item we track (PRNewsWire, 29 Oct 2026): "Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results". Rigel Pharmaceuticals announced it will report its third-quarter 2026 financial results after market close on Thursday, November 5, 2026.
Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer. The company’s current portfolio centers on commercial products and clinical-stage programs that address blood cancers and related immune-driven conditions, with an emphasis on targeted small-molecule medicines. Its marketed therapies support treatment in specialized physician markets, including hematology and oncology, while its research pipeline includes additional candidates designed to modulate key signaling pathways involved in disease progression. Rigel Pharmaceuticals also works through collaboration and licensing activities that support the development and commercialization of its products. Headquartered in South San Francisco, California, and founded in 1996, Rigel Pharmaceuticals plays a focused role in the biopharmaceutical market by supplying therapies for complex conditions with limited treatment options.
CEO Mr. Raul R. Rodriguez · 172 employees · United States · https://www.rigel.com
